13385 Marseille Cedex 05 21 matthias.canault@univ-amu.fr 22 performed early post-delivery. The patient was monitored for 5 days, and was released from 86 hospital without any haemostatic maintenance treatment. 87 Severe metrorrhagia occurred on day 11 post partum. A single emergency transfusion of 6 88 platelet concentrates was administered together with a continuous tranexamic acid infusion 89 (Fig. 1A), resulting in prompt positive clinical effects. The patient left the hospital on day 13 90 post partum; her treatment was prednisone (10 mg/d), hydroxochloroquine (400 mg/d), oral 91 tranexamic acid (1 g each 8 h for 3 days). 92 She underwent an emergency hospitalisation 38 days post partum for a severe haemorrhagic 93 first post-pregnancy menstrual period with expulsion of clots by the vaginal route. Platelet 94 count was within normal ranges. Platelets and RBC transfusions, intravenous tranexamic acid 95 and fluid infusions allowed haemodynamic stabilisation, but showed moderate haemostatic 96 efficacy. A single rFVIIa injection (90 µg/kg) stopped abnormal bleeding. The patient left the 97 hospital 4 days later.
• Some platelet disorders increase risk of haemorrhage during pregnancy and delivery.
28
• Management of bleeding diathesis during the course of pregnancy in CalDAG-GEFI 29 deficiency. 30 • Severe bleeding occurred in the postpartum period similar to that in women with 31 Glanzmann's thrombasthenia. 32 • A planned bleeding prevention strategy is required for pregnant women with CalDAG-33 GEFI deficiency. 34 Word count: 955 35 To the editor, 37 Pregnant women with inherited platelet disorders are at high risk of life-threatening 38 haemorrhage during delivery. Foetuses and newborns can also be affected, and be at risk of 39 bleeding complications (1, 2). Here we describe bleeding diathesis and its management during 40 the course of pregnancy in a young woman with severe mucocutaneous bleeding and platelet 41 dysfunction caused by calcium and diacylglycerol-guanine exchange factor I (CalDAG-GEFI) 42 deficiency recently characterised by several groups (3-6). The patient was explored after 43 informed written consent was obtained, in accordance with the Declaration of Helsinki.
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The propositus was born in 1994 from asymptomatic consanguineous parents (cousins). She 
